Novo Nordisk A/S (NYSE:NVO) received an upgrade from DBS Bank analyst Nico Chen to Hold from Sell with a price target of DKK 340. TD Cowen analyst Michael Nedelcovych also cut the price target on NVO to $70 from $105 but maintained a Buy rating, citing headwinds in the GLP-1 portfolio and potential of the oral semaglutide obesity program.

Novo Nordisk A/S (NYSE:NVO) develops pharmaceutical products for diabetes, obesity, cardiovascular conditions, and rare diseases. Despite Cramer’s criticism of the company’s management, NVO offers potential as an investment. However, other AI stocks may provide greater upside potential and less downside risk, making them more attractive options for investors.

For more investment opportunities, check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now.” This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Novo Nordisk Recieves an Upgrade From DBS, Price Cut From TD Cowen